SFTPD
Reaktivität: Human
WB
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Optimal dilution of the SFTPD antibody should be determined by the researcher.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.2 mg/mL
Buffer
0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Aliquot the SFTPD antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Target
SFTPD
(Surfactant Protein D (SFTPD))
Andere Bezeichnung
SFTPD
Hintergrund
Pulmonary surfactant is primarily responsible for lowering the surface tension at the air-liquid interface in the alveoli, a process that is essential for normal respiration. Pulmonary surfactant is a mixture of phospholipids and proteins, including four distinct surfactant-associated proteins (SPs), SP-A, SP-B, SP-C, SP-D. SP-B and SP-C are predominantly hydrophobic proteins that associate with lipids to promote the absorption of surfactant phospholipids and to reduce the surface tension in the alveoli. SP-A and SP-D are large multimeric proteins belonging to the family of calcium-dependent lectins, designated Collectins, which contribute to the innate immune system. Both SP-A and SP-D have been shown to protect against microbial challenge through binding to the lipid components of the bacterial cell wall and facilitating the rapid removal of microbials.